Older chemo regimes: FEC reduces 10-year death risk by 48% over CMF for her2-positive

[Christine MH-UK]

http://www.nlm.nih.gov/medlineplus/n...ory_33672.html

Canadian researchers looked at 639 preserved specimens from pre-menopausal women and found that it may be primarily her2 positive women who benefit from anthracycline containing regimes. 'In the study, the CEF regimen reduced the 10-year risk of death for patients with HER2-positive cancers by 48 percent, compared to similar patients placed on another regimen, called CMF (cyclophosphamide, methotrexate and fluorouracil).'

Although herceptin is, of course, even better than FEC alone, I think that this is important news for patients in poorer countries where herceptin is simply unobtainable and reason why everyone breast cancer patient should have their her2 status checked.